Search Follow us

BB Biotech (BION)

Business description

BION is a Switzerland-domiciled investment company, targeting attractive long-term returns from predominantly mid-/large-cap biotech companies with established product portfolios (sales and earnings) and promising pipeline candidates. It is benchmarked against the NASDAQ Biotech Index, but is managed bottom-up with a concentrated 20-35 stock portfolio.

Stock data

Market cap.CHF3675.8m
Last closeCHF66.35
High / Low (52 weeks)CHF74.1 / CHF62.3
Stock market listingSW, IM
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamInvestment Companies
SectorInvestment Companies

Other companies in sector Show

Aberdeen New Dawn Investment Trust Aberdeen New Thai Investment Trust
Aberdeen Private Equity Fund Aberdeen UK Tracker Trust
AcenciA Debt Strategies Acorn Income Fund
Adamas Finance Asia Alliance Trust
Altamir SCA Amphion Innovations
Aurelius Bailador Tech Investments
Baker Steel Resources Trust Bankers Investment Trust (The)
BioPharma Credit BlackRock Greater Europe Investment Trust
BlackRock Hedge Selector BlackRock Latin American Inv. Trust
British Portfolio Trust Brunner Investment Trust (The)
Canadian General Investments Carador Income Fund
CFP Sanford DeLand Free Spirit Fund. Charles Stanley
City Natural Resources Conversus Capital
CQS Rig Finance Fund CVC Credit Partners European Opps
Detour Gold Deutsche Beteiligungs
Dexion Commodities Diverse Income Trust (The)
DouglasBay Capital Dunedin Enterprise Investment Trust
DW Catalyst Fund Edinburgh Worldwide Investment Trust (The)
EJF Investments European Assets Trust
European Investment Trust (The) F&C Managed Portfolio Income
F&C Managed Portfolio Trust F&C US Smaller Companies
Fidelity Asian Values Fidelity China Special Situations
Fidelity European Values Fidelity Japan Trust
Fidelity Special Values Finsbury Growth & Income Trust
Foreign & Colonial Investment Trust Gartmore Growth Opportunities
Gartmore Irish Growth Fund Geiger Counter Limited
Genesis Emerging Markets Fund GLI Alternative Finance
Global Resources Investment Trust Golden Prospect Precious Metals
Gulf Investment Fund Hansa Trust (HAN)
HarbourVest Global Private Equity HarbourVest Senior Loans Europe
HBM Healthcare Investments Heliad Equity Partners
Henderson Alternative Strategies Trust Henderson Far East Income
Henderson Global Trust Henderson Global Trust
Henderson International Income Trust Heptagon
HSBC Infrastructure Company Infrastructure India
International Biotechnology Trust Invesco Asia Trust
Invesco Income Growth Trust Is Private Equity
JP Morgan Private Equity Limited JPMorgan Brazil Investment Trust
JPMorgan European Smaller Companies Trust JPMorgan Global Convertibles Income Fund
JPMorgan Global Growth & Income JPMorgan Indian Investment Trust
Jupiter Green Investment Trust Jupiter UK Growth Investment Trust
Jupiter US Smaller Companies JZ Capital Partners Limited
Lazard World Trust Fund Leaf Clean Energy Company
LMS Capital Lowland Investment Company
LPeC Marble Point Loan Financing
Martin Currie Asia Unconstrained Trust Martin Currie Global Portfolio Trust
Middlefield Canadian Income Miton Global Opportunities
Miton Income Opportunities Trust Murray International Trust
New City Energy Ocean Wilsons Holdings
Odyssean Investment Trust Pacific Assets Trust
Phaunos Timber Fund Polar Capital Global Healthcare Trust
Princess Private Equity Holding PXP Vietnam Fund
Rathbone Brothers RENN Universal Growth Investment Trust
Schroder AsiaPacific Fund Schroder Global Real Estate Securities
ScotGems Scottish Oriental Smaller Companies
Securities Trust of Scotland Seneca Global Income & Growth Trust
Sigma Capital Group Standard Life Equity Income Trust
Standard Life Investments Property Income Trust Standard Life Private Equity Trust
Standard Life UK Smaller Companies Strategic Equity Capital
Taiwan Fund (The) Templeton Emerging Markets Investment Trust
Tetragon Financial Group The Biotech Growth Trust
The Law Debenture Corporation The Merchants Trust
The North American Income Trust The Scottish Investment Trust
Tiso Blackstar Group Toscafund Asset Management
TR European Growth Trust UK Commercial Property REIT
Utilico Emerging Markets Trust Vietnam Enterprise Investments
Vietnam Holding Asset Management Vietnam Infrastructure Fund
VinaCapital Vietnam Opportunity Fund VinaLand
Vision Opportunity China Fund WAM Active
WAM Capital WAM Research
Witan Investment Trust Witan Pacific Investment Trust
Worldwide Healthcare Trust YFM Equity Partners

Company news

Investment summary

BB Biotech (BION) is a long-established (since 1993), Switzerland-based global investor in the innovative area of biotechnology. It is differentiated from peers by its short list of stocks (typically 30-35) and high-conviction approach, with five to eight core holdings accounting for half to two-thirds of the portfolio. While the fund can be vulnerable to short-term sentiment dips (such as in the period immediately before and after the US presidential election in 2016), its performance record is impressive in both absolute and relative terms, with a NAV total return of c 270% over five years, and NAV and share price outperformance of the benchmark NASDAQ Biotechnology index over three, six and 12 months, and three, five and 10 years to 31 October 2017 (all in Swiss franc terms). A high distribution policy of 5.0% underpins the current dividend yield of 4.3%.

Last updated on 23/11/2017

Latest video

Bitesize Briefings - BB Biotech

Key management

Prof. Dr. Thomas Szucs, Chairman
Daniel Koller, Head of Management Team
Claude Mikkelsen, Director of IR
Dr. Silvia Schanz , Investor Relations

Company address

Seestrasse 16
Postfach
8700 Kusnacht / Zurich
Germany
+41 44 267 67 00
View website